سعر كابروستينكس 0.5 مجم 2025

Cabergoline 0.5 mg tablets, pack of 8 (Cabrostinex).

• Treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults.DailyMed (FDA)

• Most common (>10%): nausea, headache, and dizziness.International label, same formulation · DailyMed (FDA)

• Uncontrolled hypertension; known hypersensitivity to ergot derivatives; history of cardiac valvular disorders or pericardial fibrosis; history of pleural, pulmonary, or retroperitoneal fibrotic disorders.International label, same formulation · DailyMed (FDA)

• Cardiac valvulopathy and pericardial fibrosis: evaluate with echocardiogram before starting; monitor periodically; discontinue if new valvular disease or pericarditis.International label, same formulation · DailyMed (FDA)
• Pleural, pulmonary and retroperitoneal fibrosis: monitor for progressive fibrosis; discontinue if fibrosis occurs.International label, same formulation · DailyMed (FDA)
• Orthostatic hypotension: check BP at baseline and during treatment; caution rising from sitting/lying.International label, same formulation · DailyMed (FDA)

• D2-antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide)MajorNot recommended for concomitant use; may reduce cabergoline effectiveness.DailyMed (FDA)

• If conception occurs during therapy, discontinue if risks to mother/fetus outweigh benefits. Avoid dopamine agonists generally during pregnancy and postpartum; risks increase with pregnancy-induced hypertension/preeclampsia/eclampsia.International label, same formulation · DailyMed (FDA)
• Not recommended in postpartum women who are breastfeeding or planning to breastfeed; avoid for lactation inhibition/suppression.International label, same formulation · DailyMed (FDA)

English text not available for this section.